Sponsored Content

While social distancing is essential, “medical distancing”—staying away from the doctor’s office for fear of contracting COVID-19—is dangerous. Just as phrma.org’s latest campaign strives to remind people that seeking care is not only safe but necessary, we see it as our duty at PatientPoint to provide patients, physician practices, and brands the support they need to ensure effective engagements are still occurring at the point of care.

Our business is driven by a deep understanding of patient and physician behaviors and desires at critical touchpoints in the care journey. We know your business relies on these insights as well. That’s why we are continually talking to our network of physicians, analysts, and industry insiders to secure proprietary data that we can use to provide you with the most up-to-date insights into the pulse of marketplace.

Here are three new insights, according to patient-level claims data and the latest results of ongoing, independent COVID-19 patient surveys.

1. Patient visits are steadily increasing and now exceeding 2019.

While the impact on patient traffic was significant during the onset of COVID-19 in late March and April, since that time primary care office visits have steadily increased and returned to near normal ranges in June and July.

2. The second COVID surge is not impacting patient traffic in physician offices.

An additional look at trends across the country, using the same patient-level claims data, uncovers that primary care practices in most states have returned to their pre-COVID patient volumes (despite the second surge).

3. Telehealth visits are leveling off.

As more patients return to the doctor’s office, we see the percentage of telehealth visits now comprising approximately 10-11% of all primary care visits (compared to about 25% at the peak of COVID in mid-April). According to our recent consumer surveys, 72% of patients say they prefer in-person appointments.

Through our ongoing data collection, we hope to separate fact from fiction about patient care and COVID-19, and provide an ongoing benchmark of real insights straight from doctors and patients during this unprecedented time. We will continue to apply what we’ve learned to ensure we make every doctor-patient engagement better at all points of care.

Keep up to date on all of our latest research and insights by visiting our COVID-19 News of the Day blog.

A record low price increase on branded drugs and changes in health insurance benefit design are just a few of the reasons that patients in the US are experiencing improved affordability for their medications, according to a new report from The IQVIA™ Institute for Human Data Science. Their research found that 71% of branded prescriptions have a final out-of-pocket cost of below $20, while just 3.6% of branded prescriptions have a cost above $125. The report, Medicine Spending and Affordability in the U.S.: Understanding Patient Costs for Medicines, discovered that “[a] rising number of prescriptions are now dispensed with a $0 payment by the patient, and now amount to 44% of all branded prescriptions in 2019, up from 36% in 2015.”

Additionally, the data found that branded prescriptions costing more than $125 largely affects those with commercial plans (44% of high-cost claims) or Medicare coverage (35% of high-cost claims). IQVIA did also find that “abandonment is higher at higher prescription cost levels, and those prescriptions may be underrepresented as those prescriptions might have been abandoned due to cost.” Of the 9% of branded and generic prescriptions that are abandoned: 5% are for medications of no cost, but 60% are when the medicine costs more than $500.

“Lower drug price growth and improvements in affordability to patients is a testament to the positive market dynamics of the American pricing system and the fact that manufacturers, health insurers and the intermediaries, such as wholesalers and benefits managers, have taken actions to reduce the burden of drug costs to patients,” said Murray Aitken, IQVIA senior vice president and executive director of the IQVIA Institute for Human Data Science, in the news release. The report examined the complexities of our current pricing system, hoping to “contribute to more transparency and understanding of the different levels of cost,” Aitken added.

“Visits to physician offices and other health care practices, which had fallen 60 percent by early April, have now rebounded and plateaued at 10 percent below prepandemic levels,” found the latest wave of research from the Harvard University, Phreesia, and the Commonwealth Fund. In-office visits are still showing a decline, even among those states which saw a surge in cases during the June and July months. However, these declines are still smaller than that of the early days of the pandemic.

Several hot spots states – including early-opening ones such as Arizona, Florida, and Texas – recorded an increase in telemedicine visits, but only a slight decrease in overall visits. “Practices in these states appear to have maintained most of their visit volume by increasing telemedicine visits and creating new safety protocols for in-person visits.”

Telemedicine use peaked in mid-April. While it has shown a decline and its current adoption has plateaued, it is still being used at a “substantially higher rate than prior to the pandemic” the report notes.

The research continued to find a large difference in visit patterns between adults and children, with adults still outpacing children. Those aged 18-64 years old showed a -4% change in visits (the smallest percent change for the week starting 7/26/2020), while children ages 3-5 represented the largest percent change at -36%. Children ages 0-2 were tracked at -32%; ages 6-17 recorded a -17%; and those aged 65-74 and 75+ both came in with a -9% each in visits.

Initial data findings were published in April 2020, with this research partnership team providing monthly updates to track trends in outpatient office visits. Click here to view more of the findings – including what impacts insurance type has had on visit rebounds and the adoption of telemedicine by Federally Qualified Health Centers (FQHC) and non-FQHC.